Sigma Healthcare Ltd (ASX: SIG) Share Price and News

Price

$2.96

Movement

0.02 (+0.68%)

as at 7 May - Closed (20 mins delayed)

52 Week Range

$1.075 - $3.32

 
1 Year Return

+130.35%

Sigma Healthcare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $33.94 billion
P/E Ratio 679.55
Dividend Yield 0.32%
Shares Outstanding 11.54 billion
Earnings per share -0.009
Dividend per share 0.01
Year To Date Return 20.23%
Earnings Yield 0.15%
Franking -
Share Price

$2.96

Day Change

0.02 (+0.68%)

52 Week Range

$1.075 - $3.32

Yesterday's Close

$2.94

Today's Open

$2.95

Days Range

$2.88 - $2.975

Volume

27,229,305

Avg. Volume (1 month)

27,182,695

Turnover

$80,134,769

as at 7 May - Closed

Sigma Healthcare Ltd (ASX: SIG)
Latest News

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Consumer Staples & Discretionary Shares

Sigma share price jumps 12% on big Chemist Warehouse news

Investors are cheering on today's update. Let's dig deeper into what is happening.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Dropsuite, Monadelphous, Sigma, and Telix shares are storming higher today

These shares are starting the week on a positive note. But why?

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Healthcare Shares

Up 175% in a year, is this why the Sigma share price is falling this week?

Sigma shares are taking a tumble again today. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why Iluka, Sigma, Wildcat, and Woodside shares are falling today

These shares are having a tough time on hump day. Why are investors hitting the sell button?

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Happy couple receiving key to apartment.
Share Market News

Best ASX 200 shares vs. best suburbs for property investment in 2024

Let's get specific about which stocks and suburban property markets delivered the best capital growth.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares race to another record high. What's next?

What's next for the new-and-improved healthcare giant?

Read more »

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Read more »

Three rockets heading to space
Record Highs

3 ASX 300 shares smashing new multi-year highs while the market struggles

The broader market is in the red on Friday but these three shares are riding high.

Read more »

A group of people at a party look upwards to the camera as they celebrate the rise of ASX value shares
Share Gainers

16 ASX shares that doubled in value last year

There were multiple ASX All Ords stocks that delivered double-or-more share price growth in 2024.

Read more »

A businessman compares the growth trajectory of property versus shares.
Share Market News

Shares vs. property: Which investment delivered the best capital growth in 2024?

Where did home values rise by almost 20%? And which ASX 200 stock more than tripled in value?

Read more »

A group of businesspeople clapping.
Best Shares

Best ASX 200 share of each market sector in 2024

Here are the No. 1 stocks for price growth in each of the 11 market sectors for 2024.

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
01 Oct 2024 $0.0050 0.00% Interim 17 Oct 2024
28 Mar 2024 $0.0050 50.00% Final 17 Apr 2024
25 Sep 2023 $0.0050 100.00% Interim 11 Oct 2023
30 Mar 2023 $0.0050 100.00% Final 18 Apr 2023
29 Sep 2022 $0.0050 100.00% Interim 12 Oct 2022
04 Apr 2022 $0.0100 100.00% Final 22 Apr 2022
24 Sep 2021 $0.0100 100.00% Interim 08 Oct 2021
06 Apr 2021 $0.0100 100.00% Final 21 Apr 2021
19 Sep 2019 $0.0100 100.00% Interim 04 Oct 2019
03 Apr 2019 $0.0200 100.00% Final 29 Apr 2019
12 Oct 2018 $0.0150 100.00% Interim 29 Oct 2018
05 Apr 2018 $0.0250 100.00% Final 20 Apr 2018
19 Sep 2017 $0.0250 100.00% Interim 05 Oct 2017
06 Apr 2017 $0.0300 100.00% Final 21 Apr 2017
20 Sep 2016 $0.0250 100.00% Interim 03 Oct 2016
06 Apr 2016 $0.0300 100.00% Final 21 Apr 2016
03 Apr 2014 $0.0200 100.00% Final 30 Apr 2014
21 Sep 2012 $0.0200 100.00% Interim 26 Oct 2012
05 Apr 2011 $0.1500 100.00% Special Cash 11 May 2011
16 Oct 2009 $0.0300 100.00% Interim 13 Nov 2009
31 Mar 2009 $0.0400 100.00% Final 07 May 2009
30 Sep 2008 $0.0300 100.00% Interim 29 Oct 2008
29 Aug 2005 $0.0200 100.00% Interim 15 Sep 2005
02 Mar 2004 $0.2000 100.00% Final 23 Mar 2004

SIG ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
6th May 2025 2025-05-06T08:25:06 Macquarie Sydney Conference PresentationYesNo8:25am152.3M
6th May 2025 2025-05-06T08:24:46 Trading UpdateYesNo8:24am2218k
16th Apr 2025 2025-04-16T12:44:13 Appendix 3Y Change of Director's Interest NoticeYesNo12:44pm3227k
25th Mar 2025 2025-03-25T10:39:43 Sigma AGM ExtensionYesNo10:39am2191k
21st Mar 2025 2025-03-21T15:43:52 Additional Clarifying Information - Appendix 4EYesNo3:43pm1152k
20th Mar 2025 2025-03-20T08:45:33 Sigma Full Year 2024/25 ASX ReleaseYesNo8:45am3290k
20th Mar 2025 2025-03-20T08:44:48 Sigma Appendix 4E & Full Year Financial ReportYesNo8:44am941.7M
7th Mar 2025 2025-03-07T17:01:18 S&P DJI Announces March 2025 Quarterly RebalanceYesNo5:01pm8179k
27th Feb 2025 2025-02-27T19:21:03 Roadshow Presentation including CW 1H25 ResultsYesNo7:21pm243.7M
27th Feb 2025 2025-02-27T13:22:51 Application for quotation of securities - SIGYesNo1:22pm616k

About Sigma Healthcare Ltd

Sigma Healthcare Ltd. engages in the manufacture and distribution of pharmaceutical products through pharmacy, grocery channels, and private label. The firm operates through the Amcal, Guardian, PharmaSave, Chemist King, and Discount Drug Stores retail brands. It also involves in the provision of services to retail pharmacists in Australia. The company was founded on July 2, 1999 and is headquartered in Rowville, Australia.

SIG Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
06 May 2025 $2.94 $-0.21 -6.67% 32,959,722 $3.09 $3.10 $2.93
05 May 2025 $3.15 $0.05 1.61% 27,153,512 $3.10 $3.16 $3.08
02 May 2025 $3.10 $0.09 2.99% 53,619,932 $3.03 $3.10 $3.02
01 May 2025 $3.01 $-0.01 -0.33% 28,087,445 $3.05 $3.09 $3.01
30 Apr 2025 $3.02 $0.00 0.00% 27,407,111 $3.02 $3.04 $3.00
29 Apr 2025 $3.02 $0.01 0.33% 18,498,204 $3.01 $3.03 $3.00
28 Apr 2025 $3.01 $0.00 0.00% 26,879,063 $3.01 $3.03 $2.99
24 Apr 2025 $3.01 $-0.06 -1.95% 18,131,333 $3.05 $3.06 $3.00
23 Apr 2025 $3.07 $0.12 4.07% 37,623,760 $3.00 $3.08 $2.98
22 Apr 2025 $2.95 $-0.03 -1.01% 12,487,291 $2.96 $2.99 $2.94
17 Apr 2025 $2.98 $-0.01 -0.33% 27,722,891 $2.99 $3.02 $2.98
16 Apr 2025 $2.99 $0.00 0.00% 18,757,612 $3.00 $3.02 $2.96
15 Apr 2025 $2.99 $-0.01 -0.33% 11,768,807 $3.00 $3.02 $2.98
14 Apr 2025 $3.00 $0.00 0.00% 21,907,222 $3.00 $3.03 $2.98
11 Apr 2025 $3.00 $0.00 0.00% 23,246,464 $2.97 $3.01 $2.95
10 Apr 2025 $3.00 $0.07 2.39% 30,596,381 $3.00 $3.02 $2.96
09 Apr 2025 $2.93 $-0.04 -1.35% 28,528,445 $2.93 $3.00 $2.91
08 Apr 2025 $2.97 $0.15 5.32% 33,609,833 $2.82 $2.98 $2.81

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
14 Apr 2025 Damien Gance Sell 100,000,000 $297,000,000
Off-market trade.
14 Feb 2025 Damien Gance Sell 40,000,000 $120,000,000
Off-market trade.
14 Feb 2025 Vikesh Ramsunder Buy 1,965,878 $6,133,539
Conversion of securities.
14 Feb 2025 Vikesh Ramsunder Exercise 1,965,878 $6,133,539
Conversion of securities. 1,010,723 - Rights
13 Feb 2025 Vikesh Ramsunder Sell 11,662,028 $34,053,121
On-market trade. Average Price
12 Feb 2025 Vikesh Ramsunder Buy 1,167,106 $3,221,212
Conversion of securities.
12 Feb 2025 Vikesh Ramsunder Exercise 1,167,106 $3,221,212
Conversion of securities. 4,921,778 - Rights
12 Feb 2025 Vikesh Ramsunder Expiry 1,945,177 $5,368,688
As advised by the company. 2,976,601 - Rights
lapse of remaining 1,945,177 EEG Rights
10 Jul 2024 Annette Carey Buy 3,662 $4,681
Directors' share plan.
10 Jul 2024 Christopher Roberts Buy 3,661 $4,680
Directors' share plan.
10 Jul 2024 Neville Mitchell Buy 4,340 $5,548
Directors' share plan.
10 Jul 2024 Kathryn (Kate) Spargo Buy 4,747 $6,067
Directors' share plan.
10 Jul 2024 Michael Sammells Buy 7,866 $10,054
Directors' share plan.
09 Jul 2024 Vikesh Ramsunder Issued 1,253,717 $1,611,026
Issue of securities. 6,088,884 - Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Christopher Graham Roberts Non-Executive Director Oct 2023
Dr Roberts has more than 40 years of experience in the medical device industry, including as the former Chief Executive Officer of Cochlear Limited from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a director of ResMed Inc until November 2017. He is currently a non-executive director of HMC Capital Ltd (ASX:HMC). HMC Capital managed HealthcCo Healthcare and Wellness REIT (ASX:HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.
Mr Neville Mitchell Non-Executive Director Feb 2023
Mr Mitchell has international healthcare and finance experience. He was Chief Financial Officer and Company Secretary at ASX-listed Cochlear Limited, a world leading medical device developer, manufacturer and seller of hearing devices. Mr Mitchell is currently the Chairman of ASX and NZX-listed Fisher&Paykel Healthcare Corporation (non-executive director from November 2018) and a non-executive director of Sonic Healthcare Limited from September 2017. He is Chair of the Sonic Audit Committee. He was formerly a non-executive director of ASX-listed Sirtex Healthcare, Osprey Medical Inc and Q'Biotics Group Limited. He has also performed roles with several industry and Government committees.
Mr Michael Sammells Non-Executive DirectorNon-Executive Chairman Feb 2020
Mr Sammells is also currently a non-executive director at AMP Limited and a director at GMBHA. He has 35 years of broad experience in finance, corporate services and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital development, mergers and acquisitions and IPOs. Further, Mr Sammells is a former Chief Financial Officer of Healthscope Limited and Medibank Private.
Mr Vikesh Ramsunder Chief Executive OfficerManaging Director Feb 2022
Mr Ramsunder has experience in pharmacy retailing, wholesaling and logistics. He spent 28 years with the Clicks Group in South Africa. This included 18 years as part of the executive team. Before becoming Clicks Group Chief Executive Officer in January 2019, Mr Ramsunder held several roles within Clicks, including Chief Operating Officer from 2015 and Managing Director of the pharmaceutical wholesale business, United Pharmaceutical Distributors from 2010.
Ms Annette May Carey Non-Executive Director Apr 2023
Ms Carey is a current non-executive director of National Intermodal Corporation and a non-executive director of the Kinetic bus group. Prior to joining Sigma, Ms Carey has held director roles within the Linfox group of companies and has been Chair or Deputy Chair of Australia Post joint ventures in the UK and China. She has previously held various senior roles within the Linfox Logistics group, progressing from General Counsel and Company Secretary to Chief Executive Officer. Ms Carey also held the position of Executive General Manager International with Australia Post. Ms Carey is a member of Chief Executive Women.
Mr Jack Gance Non-Executive Director Feb 2025
Mr D Gance is a qualified pharmacist who joined MyChemist in 1998 and is currently the Chief Commercial Officer of Chemist Warehouse. Mr D Gance was the first Chemist Warehouse Franchisee opening the first Chemist Warehouse pharmacy in June 2000.
Ms Danielle Di Pilla Executive Director Feb 2025
Ms Di Pilla is a qualified pharmacist who is currently the Chief People Officer at Chemist Warehouse. Ms Di Pilla established DPP Pharmaceuticals Pty Ltd (DPP) in 2000 and is the founder of brands such as Goat Soap, which has had international success. Ms Di Pilla has been the managing director of DPP since it was incorporated. DPP is a wholly owned subsidiary of Chemist Warehouse. Ms Di Pilla also sits on the Board of Gotcha4Life.
Mr Mario Verrocchi Executive Director Feb 2025
Mr Verrocchi joined Jack and Sam Gance's pharmacy group in 1982. Mr Verrocchi established MyChemist with Jack Gance and Sam Gance in 1997 and subsequently created the Chemist Warehouse chain with Messrs Gance in 2000. He is currently Chief Executive Officer of Chemist Warehouse.
Mr Damien Gance Executive Director Feb 2025
Mr J Gance as a pharmacist in 1967 and opened his first pharmacy store in Reservoir, Victoria, with Sam in 1972. In 1997, Mr J Gance, Sam Gance and Mario Verrocchi, established MyChemist and opened the first MyChemist store. In 2000, Mr J Gance, along with Mr Sam Gance and Mr Verrocchi, established the Chemist Warehouse chain and opened the first Chemist Warehouse store. Mr J Gance also created the brands Le Specs, Le Tan and Colours of Australis.
Ms Kara McGowan General CounselCompany Secretary Oct 2021
-
Kara McGowan General CounselCompany Secretary
-
Mr M Conway Chief Financial Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 871,241,938 14.61%
Citicorp Nominees Pty Limited 445,477,631 7.47%
J P Morgan Nominees Australia Pty Limited 359,556,170 6.03%
Dgsr Family Foundation Pty Ltd 353,829,615 5.93%
Av Family Foundation Pty Ltd 313,784,873 5.26%
Mjv Family Foundation Pty Ltd 313,784,873 5.26%
Mr Sunil Narula 165,893,114 2.78%
Bond Street Custodians Limited 150,545,209 2.52%
Mat Family Foundation Pty Ltd 148,144,781 2.48%
HMC Capital Partners Holdings Pty Ltd 103,399,008 1.73%
Ms Nancy Fei Fei Jian 86,118,340 1.44%
HSBC Custody Nominees (Australia) Limited Gsco Eca 75,333,468 1.26%
Mr Azman Rashid Haroon 64,502,845 1.08%
Ms Danielle Di Pilla 61,243,218 1.03%
Mr Claudio Avendano 55,986,398 0.94%
Citicorp Nominees Pty Limited i 51,603,737 0.87%
Bond Street Custodians Limited i 48,455,727 0.81%
Di Pilla Investments Pty Ltd 44,228,054 0.74%
Mr William Ho 41,669,145 0.70%
Bond Street Custodians Limited ii 41,505,949 0.73%
Mr Anthony Paul Bassaly 39,768,975 0.67%

Profile

since

Note